Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Research & Development for 3 consecutive years, with $38.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 10.6% to $38.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141.8 million through Dec 2025, down 6.32% year-over-year, with the annual reading at $141.8 million for FY2025, 6.32% down from the prior year.
  • Research & Development hit $38.6 million in Q4 2025 for NewAmsterdam Pharma, up from $31.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $44.8 million in Q1 2025 to a low of $27.5 million in Q2 2025.
  • Historically, Research & Development has averaged $37.7 million across 3 years, with a median of $38.5 million in 2024.
  • Biggest five-year swings in Research & Development: increased 11.76% in 2024 and later dropped 28.3% in 2025.
  • Year by year, Research & Development stood at $41.3 million in 2023, then fell by 15.49% to $34.9 million in 2024, then grew by 10.6% to $38.6 million in 2025.
  • Business Quant data shows Research & Development for NAMS at $38.6 million in Q4 2025, $31.0 million in Q3 2025, and $27.5 million in Q2 2025.